Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 94,943 shares at $53.48 ($5.1M) on 2021-12-01, disclosed to the SEC on 2021-12-03.
Open-market sale of $5.1M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.48 | 4,243 | $227K | 4.4% |
| 2 | $53.48 | 2,766 | $148K | 2.9% |
| 3 | $53.48 | 2,766 | $148K | 2.9% |
| 4 | $53.48 | 4,243 | $227K | 4.4% |
| 5 | $54.67 | 3,372 | $184K | 3.6% |
| 6 | $54.67 | 5,168 |
| $283K |
| 5.5% |
| 7 | $54.67 | 5,168 | $283K | 5.5% |
| 8 | $54.67 | 3,372 | $184K | 3.6% |
| 9 | $55.71 | 2,528 | $141K | 2.7% |
| 10 | $55.71 | 1,649 | $92K | 1.8% |
| 11 | $55.71 | 1,649 | $92K | 1.8% |
| 12 | $55.71 | 2,528 | $141K | 2.7% |
| 13 | $56.27 | 1,021 | $57K | 1.1% |
| 14 | $56.27 | 1,021 | $57K | 1.1% |
| 15 | $56.27 | 1,566 | $88K | 1.7% |
| 16 | $56.27 | 1,566 | $88K | 1.7% |
| 17 | $51.99 | 79 | $4K | 0.1% |
| 18 | $52.00 | 52 | $3K | 0.1% |
| 19 | $53.17 | 6,372 | $339K | 6.6% |
| 20 | $53.17 | 6,372 | $339K | 6.6% |
| 21 | $53.17 | 4,155 | $221K | 4.3% |
| 22 | $53.17 | 4,155 | $221K | 4.3% |
| 23 | $53.86 | 8,747 | $471K | 9.2% |
| 24 | $53.86 | 5,705 | $307K | 6.0% |
| 25 | $53.86 | 5,705 | $307K | 6.0% |
| 26 | $53.86 | 8,747 | $471K | 9.2% |
| 27 | $54.67 | 90 | $5K | 0.1% |
| 28 | $54.67 | 138 | $8K | 0.1% |
| Total | $54.09 avg | 94,943 | $5.1M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |
| KROS | SELL | 2021-10-21 | $598K | — | Filing → |